Literature DB >> 17305793

CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy.

M Lajer, L Tarnow, S Andersen, H-H Parving.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17305793     DOI： 10.1111/j.1464-5491.2007.02086.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN： 0742-3071            Impact factor:   4.359


× No keyword cloud information.
  3 in total

Review 1.  Eicosanoids, β-cell function, and diabetes.

Authors:  Pengcheng Luo; Mong-Heng Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-03       Impact factor: 3.072

2.  CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.

Authors:  Melanie S Joy; Kimberly Dornbrook-Lavender; Joyce Blaisdell; Tandrea Hilliard; Tammy Boyette; Yichun Hu; Susan L Hogan; Corina Candiani; Ronald J Falk; Joyce A Goldstein
Journal:  Eur J Clin Pharmacol       Date:  2009-08-11       Impact factor: 2.953

Review 3.  Applications of CYP450 testing in the clinical setting.

Authors:  C F Samer; K Ing Lorenzini; V Rollason; Y Daali; J A Desmeules
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.